Approaches for the discovery of drugs that target K Na 1.1 channels in KCNT1-associated epilepsy

References

• Łukawski K, Czuczwar SJ. Developing precision treatments for epilepsy using patient and animal models. Expert Rev Neurother. 2021;21:1241–1250.
   PubMed Web of Science ®Google Scholar
• Thijs RD, Surges R, O’Brien TJ, et al. Epilepsy in adults. Lancet. 2019;393:689–701.
   PubMed Web of Science ®Google Scholar
• Longo A, Houot M, Herlin B, et al. Distinctive neuropsychological profiles of lateral temporal lobe epilepsy. Epilepsy Behav. 2021;125:108411.
   PubMed Web of Science ®Google Scholar
• Perucca P, Bahlo M, Berkovic SF. The genetics of epilepsy. Annu Rev Genomics Hum Genet. 2020;21:205–230.
   PubMed Web of Science ®Google Scholar
• Servilha-Menezes G, Garcia-Cairasco N. A complex systems view on the current hypotheses of epilepsy pharmacoresistance. Epilepsia Open. 2022;7(Suppl. 1):S8–S22.
   PubMedGoogle Scholar
• Perucca P, Perucca E. Identifying mutations in epilepsy genes: impact on treatment selection. Epilepsy Res. 2019;152:18–30.
   PubMed Web of Science ®Google Scholar
• Cole BA, Clapcote SJ, Muench SP, et al. Targeting K(Na)1.1 channels in KCNT1-associated epilepsy. Trends Pharmacol Sci. 2021;42:700–713.
   PubMed Web of Science ®Google Scholar
• Yao JA, Trybulski EJ, Tseng GN. Quinidine preferentially blocks the slow delayed rectifier potassium channel in the rested state. J Pharmacol Exp Ther. 1996;279:856–864.
   PubMed Web of Science ®Google Scholar
• Milligan CJ, Pachernegg S. Utilising automated electrophysiological platforms in epilepsy research. Methods Mol Biol. 2021;2188:133–155.
   PubMedGoogle Scholar
• Barcia G, Fleming MR, Deligniere A, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet. 2012;44:1255–1259.
   PubMed Web of Science ®Google Scholar
• Milligan CJ, Li M, Gazina EV, et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol. 2014;75:581–590.
   PubMed Web of Science ®Google Scholar
• Kim GE, Kronengold J, Barcia G, et al. Human slack potassium channel mutations increase positive cooperativity between individual channels. Cell Rep. 2014;9:1661–1672.
   PubMed Web of Science ®Google Scholar
• Quraishi IH, Stern S, Mangan KP, et al. An epilepsy-associated KCNT1 mutation enhances excitability of human iPSC-derived neurons by increasing Slack KNa currents. J Neurosci. 2019;39:7438–7449.
   PubMed Web of Science ®Google Scholar
• McTague A, Nair U, Malhotra S, et al. Clinical and molecular characterization of KCNT1- related severe early-onset epilepsy. Neurology. 2018;90:E55–66.
   PubMed Web of Science ®Google Scholar
• Quraishi IH, Mercier MR, McClure H, et al. Impaired motor skill learning and altered seizure susceptibility in mice with loss or gain of function of the Kcnt1 gene encoding slack (KNa1.1) Na+-activated K+ channels. Sci Rep. 2020;10:3213.
   PubMed Web of Science ®Google Scholar
• Evely KM, Pryce KD, Bhattacharjee A. The Phe932Ile mutation In KCNT1 channels associated with severe epilepsy, delayed myelination and leukoencephalopathy produces a loss- of-function channel phenotype. Neuroscience. 2017;351:65–70.
   PubMed Web of Science ®Google Scholar
• Tang QY, Zhang FF, Xu J, et al. Epilepsy-related slack channel mutants lead to channel over-activity by two different mechanisms. Cell Rep. 2016;14:129–139.
   PubMed Web of Science ®Google Scholar
• Mikati MA, Jiang YH, Carboni M, et al. Quinidine in the treatment of KCNT1- positive epilepsies. Ann Neurol. 2015;78:995–999.
   PubMed Web of Science ®Google Scholar
• Rizzo F, Ambrosino P, Guacci A, et al. Characterization of two de novo KCNT1 mutations in children with malignant migrating partial seizures in infancy. Mol Cell Neurosci. 2016;72:54–63.
   PubMed Web of Science ®Google Scholar
• Cole BA, Johnson RM, Dejakaisaya H, et al. Structure-based identification and characterization of inhibitors of the epilepsy-associated K(Na)1.1 (KCNT1) potassium channel. iScience. 2020;23:101100.
   PubMed Web of Science ®Google Scholar
• Villa C, Combi R. Potassium channels and human epileptic phenotypes: an updated overview. Front Cell Neurosci. 2016;10:81.
   PubMed Web of Science ®Google Scholar
• Miceli F, Guerrini R, Nappi M, et al. Distinct epilepsy phenotypes and response to drugs in KCNA1 gain- and loss-of function variants. Epilepsia. 2022;63:e7–e14.
   PubMed Web of Science ®Google Scholar
• Møller RS, Heron SE, Larsen LHG, et al. Mutations in KCNT1 cause a spectrum of focal epilepsies. Epilepsia. 2015;56:e114–e20.
   PubMed Web of Science ®Google Scholar
• Johannesen KM, Liu Y, Koko M, et al. Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications. Brain. 2022;145:2991–3009.
   PubMedGoogle Scholar
• Shore AN, Colombo S, Tobin WF, et al. Reduced GABAergic neuron excitability, altered synaptic connectivity, and seizures in a KCNT1 gain-of-function mouse model of childhood epilepsy. Cell Rep. 2020;33:108303.
   PubMed Web of Science ®Google Scholar
• Fleming MR, Brown MR, Kronengold J, et al. Stimulation of slack K+ channels alters mass at the plasma membrane by triggering dissociation of a phosphatase-regulatory complex. Cell Rep. 2016;16:2281–2288.
   PubMed Web of Science ®Google Scholar
• Kuchenbuch M, Nabbout R, Yochum M, et al., In silico model reveals the key role of GABA in KCNT1-epilepsy in infancy with migrating focal seizures. Epilepsia. 2021;62(3): 683–697.
   PubMed Web of Science ®Google Scholar
• Bonardi CM, Heyne HO, Fiannacca M, et al. KCNT1-related epilepsies and epileptic encephalopathies: phenotypic and mutational spectrum. Brain. 2021;144:3635–3650.
   PubMed Web of Science ®Google Scholar
• Gertler T, Bearden D, Bhattacharjee A, et al. KCNT1-related epilepsy. In: Adam MP, Ardinger HH, Pagon RA, editors. GeneReviews®. Seattle: University of Washington; 2018:1993–2021.
   Google Scholar
• Cornet MC, Cilio MR. Genetics of neonatal-onset epilepsies. Handb Clin Neurol. 2019;162:415–433.
   PubMedGoogle Scholar
• Fukuoka M, Kuki I, Kawawaki H, et al. Quinidine therapy for West syndrome with KCNTI mutation: a case report. Brain Dev. 2017;39(1):80–83.
   PubMed Web of Science ®Google Scholar
• Jia Y, Lin Y, Li J, et al. Quinidine therapy for Lennox-Gastaut Syndrome with KCNT1 mutation. A case report and literature review. Front Neurol. 2019;10:64.
   PubMed Web of Science ®Google Scholar
• Shi X, Chen J, Lu Q, et al. Whole-exome sequencing revealing de novo heterozygous variant of KCNT1 in a twin discordant for benign epilepsy with centrotemporal spikes. J Paediatr Child Heal. 2018;54:709–710.
   PubMed Web of Science ®Google Scholar
• Tsang MH, Leung GK, Ho AC, et al. Exome sequencing identifies molecular diagnosis in children with drug-resistant epilepsy. Epilepsia Open. 2018;4:63–72.
   PubMedGoogle Scholar
• Magleby KL. Stimulation of slack K+ channels alters mass at the plasma membrane by triggering dissociation of a phosphatase-regulatory complex. Nature. 2017;541(7635):3635–3650.
   Google Scholar
• Matthies D, Bae C, Toombes GE, et al. Single-particle cryo-EM structure of a voltage-activated potassium channel in lipid nanodiscs. Elife. 2018;7:e37558.
   PubMed Web of Science ®Google Scholar
• Mackie AR, Byron KL. Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention. Mol Pharmacol. 2008;74:1171–1179.
   PubMed Web of Science ®Google Scholar
• Hong L, Pathak MM, Kim IH, et al. Voltage-sensing domain of voltage-gated proton channel Hv1 shares mechanism of block with pore domains. Neuron. 2013;77:274–287.
   PubMed Web of Science ®Google Scholar
• Cuello LG, Jogini V, Cortes DM, et al. Structural mechanism of C-type inactivation in K(+) channels. Nature. 2010;466:203–208.
   PubMed Web of Science ®Google Scholar
• Hoshi T, Zagotta WN, Aldrich RW. Two types of inactivation in Shaker K+ channels: effects of alterations in the carboxy-terminal region. Neuron. 1991;7:547–556.
   PubMed Web of Science ®Google Scholar
• Hoshi T, Armstrong CM. C-type inactivation of voltage-gated K+ channels: pore constriction or dilation? J Gen Physiol. 2013;141:151–160.
   PubMed Web of Science ®Google Scholar
• Smith RS, Walsh CA. Ion channel functions in early brain development. Trends Neurosci. 2020;43:103–114.
   PubMed Web of Science ®Google Scholar
• Ehinger R, Kuret A, Matt L, et al. Slack K+ channels attenuate NMDA-induced excitotoxic brain damage and neuronal cell death. FASEB J. 2021;35:e21568.
   PubMed Web of Science ®Google Scholar
• Liu X, Stan Leung L. Sodium-activated potassium conductance participates in the depolarizing afterpotential following a single action potential in rat hippocampal CA1 pyramidal cells. Brain Res. 2004;1023:185–192.
   PubMed Web of Science ®Google Scholar
• Franceschetti S, Lavazza T, Curia G, et al. Na+-activated K+ current contributes to postexcitatory hyperpolarization in neocortical intrinsically bursting neurons. J Neurophysiol. 2003;89:2101–2111.
   PubMed Web of Science ®Google Scholar
• Yang B, Desai R, Kaczmarek LK. Slack and Slick KNa channels regulate the accuracy of timing of auditory neurons. J Neurosci. 2007;27:2617–2627.
   PubMed Web of Science ®Google Scholar
• Rizzi S, Knaus HG, Schwarzer C. Differential distribution of the sodium-activated potassium channels slick and slack in mouse brain. J Comp Neurol. 2016;524:2093–2116.
   PubMed Web of Science ®Google Scholar
• Bausch AE, Dieter R, Nann Y, et al. The sodium-activated potassium channel Slack is required for optimal cognitive flexibility in mice. Learn Mem. 2015;22:323–335.
   PubMed Web of Science ®Google Scholar
• Lu R, Bausch AE, Kallenborn-Gerhardt W, et al. Slack channels expressed in sensory neurons control neuropathic pain in mice. J Neurosci. 2015;35:1125–1135.
   PubMed Web of Science ®Google Scholar
• Huang F, Wang X, Ostertag EM, et al. TMEM16C facilitates Na(+)-activated K+ currents in rat sensory neurons and regulates pain processing. Nat Neurosci. 2013;16:1284–1290.
   PubMed Web of Science ®Google Scholar
• Evely KM, Pryce KD, Bausch AE, et al. Slack KNa channels influence dorsal horn synapses and nociceptive behavior. Mol Pain. 2017;13:1744806917714342.
   Web of Science ®Google Scholar
• Reijntjes DOJ, Lee JH, Park S, et al. Sodium-activated potassium channels shape peripheral auditory function and activity of the primary auditory neurons in mice. Sci Rep. 2019;9:2573.
   PubMed Web of Science ®Google Scholar
• Hite RK, Yuan P, Li Z, et al. Cryo-electron microscopy structure of the Slo2.2 Na(+)-activated K(+) channel. Nature. 2015;527:198–203.
   PubMed Web of Science ®Google Scholar
• Bartolini E, Campostrini R, Kiferle L, et al. Epilepsy and brain channelopathies from infancy to adulthood. Neurol Sci. 2020;41:749–761.
   PubMed Web of Science ®Google Scholar
• Ali SR, Malone TJ, Zhang Y, et al. Phactr1 regulates Slack (KCNT1) channels via protein phosphatase 1 (PP1). FASEB J. 2020;34:1591–1601.
   PubMed Web of Science ®Google Scholar
• Kaczmarek LK. Slack, slick and sodium-activated potassium channels. ISRN Neurosci. 2013;2013:354262.
   PubMedGoogle Scholar
• Wray D. Structure and function of ion channels. Eur Biophys J. 2009;38:271–272.
   PubMed Web of Science ®Google Scholar
• Hill CL, Stephens GJ. An introduction to patch clamp recording. Methods Mol Biol. 2021;2188:1–19.
   PubMedGoogle Scholar
• Bébarová M. Advances in patch clamp technique: towards higher quality and quantity. Gen Physiol Biophys. 2012;31:131–140.
   PubMed Web of Science ®Google Scholar
• Martin HC, Kim GE, Pagnamenta AT, et al. Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis. Hum Mol Genet. 2014;23:3200–3211.
   PubMed Web of Science ®Google Scholar
• Martinac B. Single-molecule FRET studies of ion channels. Prog Biophys Mol Biol. 2017;130(Pt B):192–197.
   PubMedGoogle Scholar
• Wang S, Lee SJ, Maksaev G, et al. Potassium channel selectivity filter dynamics revealed by single-molecule FRET. Nat Chem Biol. 2019;15:377–383.
   PubMed Web of Science ®Google Scholar
• Wang S, Brettmann JB, Nichols CG. Studying structural dynamics of potassium channels by single-molecule FRET. Methods Mol Biol. 2018;1684:163–180.
   PubMedGoogle Scholar
• Yamamura H, Suzuki Y, Imaizumi Y. New light on ion channel imaging by total internal reflection fluorescence (TIRF) microscopy. J Pharmacol Sci. 2015;128:1–7.
   PubMed Web of Science ®Google Scholar
• Tedeschi G, Scipioni L, Papanikolaou M, et al. Fluorescence Fluctuation Spectroscopy enables quantification of potassium channel subunit dynamics and stoichiometry. Sci Rep. 2021;11:1071.
   PubMed Web of Science ®Google Scholar
• Hite RK, MacKinnon R. Structural titration of Slo2.2, a Na +-Dependent K+ Channel. Cell. 2017;168:390–399.
   PubMed Web of Science ®Google Scholar
• Schmidpeter PAM, Nimigean CM. Correlating ion channel structure and function. Methods Enzymol. 2021;652:3–30.
   PubMed Web of Science ®Google Scholar
• Normand EA, Alaimo JT, Van den Veyver IB. Exome and genome sequencing in reproductive medicine. Fertil Steril. 2018;109:213–220.
   PubMed Web of Science ®Google Scholar
• Jelin AC, Vora N. Whole exome sequencing: applications in prenatal genetics. Obstet Gynecol Clin North Am. 2018;45:69–81.
   PubMed Web of Science ®Google Scholar
• Petrovski S, Aggarwal V, Giordano JL, et al. Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study. Lancet. 2019;393:758–767.
   PubMed Web of Science ®Google Scholar
• Wapner RJ, Martin CL, Levy B, et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med. 2012;367:2175–2184.
   PubMed Web of Science ®Google Scholar
• Rabbani B, Mahdieh N, Hosomichi K, et al. Next-generation sequencing: impact of exome sequencing in characterizing Mendelian disorders. J Hum Genet. 2012;57:621–632.
   PubMed Web of Science ®Google Scholar
• Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145–1147.
   PubMed Web of Science ®Google Scholar
• Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007;318:1920–1923.
   PubMed Web of Science ®Google Scholar
• Ohnuki M, Takahashi K. Present and future challenges of induced pluripotent stem cells. Philos Trans R Soc Lond B Biol Sci. 2015;370:20140367.
   PubMed Web of Science ®Google Scholar
• Poisson K, Wong M, Lee C, et al. Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: an open-label, prospective, interventional study. Eur J Paediatr Neurol. 2020;25:77–81.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;377:699–700.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment‐resistant epilepsy: an open‐label interventional trial. Lancet Neurol. 2016;15:270–278.
   PubMed Web of Science ®Google Scholar
• Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia. 2018;59:1540–1548.
   PubMed Web of Science ®Google Scholar
• Millar SA, Stone NL, Bellman ZD, et al. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol. 2019;85:1888–1900.
   PubMed Web of Science ®Google Scholar
• Saade D, Joshi C. Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report. Pediatr Neurol. 2015;52:544–547.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:1888–1897.
   PubMed Web of Science ®Google Scholar
• Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085–1096.
   PubMed Web of Science ®Google Scholar
• Abdelnour E, Gallentine W, McDonald M, et al. Does age affect response to quinidine in patients with KCNT1 mutations? Report of three new cases and review of the literature. Seizure. 2018;55:1–3.
   PubMed Web of Science ®Google Scholar
• Amin MR, Ali DW. Pharmacology of medical cannabis. Adv Exp Med Biol. 2019;1162:151–165.
   PubMed Web of Science ®Google Scholar
• Freeman AM, Petrilli K, Lees R, et al. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev. 2019;107:696–712.
   PubMed Web of Science ®Google Scholar
• Hermann D, Schneider M. Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review. Curr Pharm Des. 2012;18:4897–4905.
   PubMed Web of Science ®Google Scholar
• Campos AC, Fogaça MV, Sonego AB, et al. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res. 2016;112:119–127.
   PubMed Web of Science ®Google Scholar
• Campos AC, Moreira FA, Gomes FV, et al. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012;367:3364–3378.
   PubMed Web of Science ®Google Scholar
• Calapai F, Cardia L, Sorbara EE, et al. Cannabinoids, blood-brain barrier, and brain disposition. Pharmaceutics. 2020;12:265.
   PubMed Web of Science ®Google Scholar
• Kozela E, Lev N, Kaushansky, et al. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol. 2011;163:1507–1519.
   PubMed Web of Science ®Google Scholar
• Cohen K, Weizman A, Weinstein A. Modulatory effects of cannabinoids on brain neurotransmission. Eur J Neurosci. 2019;50:2322–2345.
   PubMed Web of Science ®Google Scholar
• Madaan P, Jauhari P, Gupta A, et al. A quinidine non responsive novel KCNT1 mutation in an Indian infant with epilepsy of infancy with migrating focal seizures. Brain Dev. 2018;40:229–232.
   PubMed Web of Science ®Google Scholar
• Li H, Liu Y, Tian D, et al. Overview of cannabidiol (CBD) and its analogues: structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer’s disease. Eur J Med Chem. 2020;192:11216.
   Web of Science ®Google Scholar
• Massi A, Vaccani S, Bianchessi B, et al. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci. 2006;63:2057–2066.
   PubMed Web of Science ®Google Scholar
• Sales AJ, Fogaça MV, Sartim AG, et al. Cannabidiol induces rapid and sustained antidepressant-like effects through increased BDNF signaling and synaptogenesis in the prefrontal cortex. Mol Neurobiol. 2019;56:1070–1081.
   PubMed Web of Science ®Google Scholar
• Miziak B, Czuczwar S. Advances in the design and discovery of novel small molecule drugs for the treatment of Dravet Syndrome. Expert Opin Drug Discov. 2021;16:579–593.
   PubMed Web of Science ®Google Scholar
• Jain A, Jack J. Quinidine 2021. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021. Available at: https://europepmc.org/article/MED/31194350.
   Google Scholar
• Vitali Serdoz L, Rittger H, Furlanello F, et al. Quinidine-A legacy within the modern era of antiarrhythmic therapy. Pharmacol Res. 2019;144:257–263.
   PubMed Web of Science ®Google Scholar
• White NJ, Looareesuwan S, Warrell DA, et al. Quinidine in falciparum malaria. Lancet. 1981;2(8255):1069–1071.
   PubMed Web of Science ®Google Scholar
• Sheets MF, Fozzard HA, Lipkind GM, et al. Sodium channel molecular conformations and antiarrhythmic drug affinity. Trends Cardiovasc Med. 2010;20:16–21.
   PubMed Web of Science ®Google Scholar
• Cheng KI, Lin IL, Chang LL, et al. Application of quinidine on rat sciatic nerve decreases the amplitude and increases the latency of evoked responses. Anesth. 2014;28:559–568.
   Google Scholar
• Sokolov AY, Lyubashina OA, Berkovich RR, et al. Intravenous dextromethorphan/quinidine inhibits activity of dura-sensitive spinal trigeminal neurons in rats. Eur J Pain. 2015;19:1086–1094.
   PubMed Web of Science ®Google Scholar
• Bearden D, Strong A, Ehnot J, et al. Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol. 2014;76:457–461.
   PubMed Web of Science ®Google Scholar
• Fitzgerald MP, Fiannacca M, Smith DM, et al. Treatment responsiveness in KCNT1-related epilepsy. Neurotherapeutics. 2019;16(3):848–857.
   PubMed Web of Science ®Google Scholar
• Data JL, Wilkinson GR, Nies AS. Interaction of quinidine with anticonvulsant drugs. N Engl J Med. 1976;294:699–702.
   PubMed Web of Science ®Google Scholar
• Yoshitomi S, Takahashi Y, Yamaguchi T, et al. Quinidine therapy and therapeutic drug monitoring in four patients with KCNT1 mutations. Epileptic Disord. 2019;21:48–54.
   PubMed Web of Science ®Google Scholar
• Numis AL, Nair U, Datta AN, et al. Lack of response to quinidine in KCNT1-related neonatal epilepsy. Epilepsia. 2018;59:1889–1898.
   PubMed Web of Science ®Google Scholar
• Dilena R, DiFrancesco JC, Soldovieri MV, et al. Early treatment with quinidine in 2 patients with epilepsy of infancy with migrating focal seizures (EIMFS) due to gain-of-function KCNT1 mutations: functional studies, clinical responses, and critical issues for personalized therapy. Neurotherapeutics. 2018;15:1112–1126.
   PubMed Web of Science ®Google Scholar
• Delanty N, Cavalleri G. Genomics-guided precise anti-epileptic drug development. Neurochem Res. 2017;42:2084–2088.
   PubMed Web of Science ®Google Scholar